SE426319B - Forfarande for framstellning av substituerade fenylketoner med sedativ, muskelrelaxerande och antikonvulsiv verkan - Google Patents

Forfarande for framstellning av substituerade fenylketoner med sedativ, muskelrelaxerande och antikonvulsiv verkan

Info

Publication number
SE426319B
SE426319B SE7509268A SE7509268A SE426319B SE 426319 B SE426319 B SE 426319B SE 7509268 A SE7509268 A SE 7509268A SE 7509268 A SE7509268 A SE 7509268A SE 426319 B SE426319 B SE 426319B
Authority
SE
Sweden
Prior art keywords
phenylketons
sedative
substituted
procedure
preparation
Prior art date
Application number
SE7509268A
Other languages
English (en)
Swedish (sv)
Other versions
SE7509268L (sv
Inventor
C H Hassall
W H Johnson
A Krohn
C E Smithen
W A Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SE7509268L publication Critical patent/SE7509268L/xx
Publication of SE426319B publication Critical patent/SE426319B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • C07K5/06095Arg-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
SE7509268A 1974-08-20 1975-08-19 Forfarande for framstellning av substituerade fenylketoner med sedativ, muskelrelaxerande och antikonvulsiv verkan SE426319B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB36567/74A GB1517164A (en) 1974-08-20 1974-08-20 Substituted-phenyl ketones and a process for the manufacture thereof
GB2182175 1975-05-21

Publications (2)

Publication Number Publication Date
SE7509268L SE7509268L (sv) 1976-02-23
SE426319B true SE426319B (sv) 1982-12-27

Family

ID=26255542

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7509268A SE426319B (sv) 1974-08-20 1975-08-19 Forfarande for framstellning av substituerade fenylketoner med sedativ, muskelrelaxerande och antikonvulsiv verkan

Country Status (19)

Country Link
JP (1) JPS6018656B2 (US08080257-20111220-C00005.png)
AR (1) AR217041A1 (US08080257-20111220-C00005.png)
AT (1) AT348985B (US08080257-20111220-C00005.png)
AU (1) AU502104B2 (US08080257-20111220-C00005.png)
CA (1) CA1177069A (US08080257-20111220-C00005.png)
CH (1) CH620900A5 (US08080257-20111220-C00005.png)
DD (1) DD123086A5 (US08080257-20111220-C00005.png)
DE (1) DE2537069A1 (US08080257-20111220-C00005.png)
DK (1) DK149284C (US08080257-20111220-C00005.png)
ES (1) ES440315A1 (US08080257-20111220-C00005.png)
FI (1) FI66592C (US08080257-20111220-C00005.png)
FR (1) FR2282261A1 (US08080257-20111220-C00005.png)
GB (1) GB1517164A (US08080257-20111220-C00005.png)
IL (1) IL47936A (US08080257-20111220-C00005.png)
LU (1) LU73219A1 (US08080257-20111220-C00005.png)
NL (1) NL7509884A (US08080257-20111220-C00005.png)
NO (1) NO150199C (US08080257-20111220-C00005.png)
PH (1) PH16616A (US08080257-20111220-C00005.png)
SE (1) SE426319B (US08080257-20111220-C00005.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2754112A1 (de) * 1977-12-05 1979-06-13 Kali Chemie Pharma Gmbh 1,4-benzodiazepinderivate, ihre salze und diese verbindungen enthaltende arzneipraeparate
IN184976B (US08080257-20111220-C00005.png) * 1996-06-13 2000-10-14 Ranbaxy Lab Ltd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3709898A (en) * 1971-02-09 1973-01-09 Upjohn Co Process for the production of triazolobenzodiazepines and intermediates
JPS526861B2 (US08080257-20111220-C00005.png) * 1972-05-27 1977-02-25
ZA735932B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Benzodiazepine derivatives

Also Published As

Publication number Publication date
SE7509268L (sv) 1976-02-23
NL7509884A (nl) 1976-02-24
CH620900A5 (en) 1980-12-31
LU73219A1 (US08080257-20111220-C00005.png) 1977-04-15
DK149284B (da) 1986-04-21
JPS51125048A (en) 1976-11-01
PH16616A (en) 1983-11-28
AR217041A1 (es) 1980-02-29
NO150199C (no) 1984-09-05
ES440315A1 (es) 1977-09-16
IL47936A (en) 1980-01-31
AU502104B2 (en) 1979-07-12
FR2282261A1 (fr) 1976-03-19
NO752876L (US08080257-20111220-C00005.png) 1976-02-23
AT348985B (de) 1979-03-12
DK149284C (da) 1986-10-13
FI66592C (fi) 1984-11-12
DK373975A (da) 1976-02-21
AU8407475A (en) 1977-02-24
IL47936A0 (en) 1975-11-25
JPS6018656B2 (ja) 1985-05-11
GB1517164A (en) 1978-07-12
FR2282261B1 (US08080257-20111220-C00005.png) 1978-11-10
NO150199B (no) 1984-05-28
DE2537069A1 (de) 1976-03-04
FI66592B (fi) 1984-07-31
DD123086A5 (US08080257-20111220-C00005.png) 1976-11-20
CA1177069A (en) 1984-10-30
DE2537069C2 (US08080257-20111220-C00005.png) 1988-09-08
ATA642175A (de) 1978-08-15
FI752350A (US08080257-20111220-C00005.png) 1976-02-21

Similar Documents

Publication Publication Date Title
SE384856B (sv) Sett att framstella indolderivat med anti-inflammatorisk, analgetisk och antipyretisk verkan
SE434946B (sv) Forfarande for framstellning av acylsackariner och acyl-3-oxo-1,2-densisotiazoliner
SE423996B (sv) Forfarande for framstellning av daunomycin- och adriamycin-derivat
SE413244B (sv) Forfarandefor framstellning av bensopyraner med analgetisk verkan
SE421319B (sv) Forfarande for framstellning av etbara polysackarider och polysackaridderivat
SE429338B (sv) Forfarande for framstellning av substituerade 2-bensylpyrrolidiner med terapeutisk verkan
SE7505736L (sv) Polylaurinlactam, forfarande for framstellning av hogre polylactamer och deras anvendning
SE437026B (sv) Forfarande for framstellning av bensopyranderivat med antiallergisk verkan
SE434263B (sv) Forfarande for framstellning av kloretylnitrosokarbamider med antitumorverkan
SE411671B (sv) Forfarande for framstellning av tripeptidderivat med terapeutisk verkan
SE398499B (sv) Forfarande for framstellning av 2,4,5,6-tetrahydrocyklopenta/c/purrol-4-karboxamider och -4-tiokarboxamider med terapeutisk verkan
SE7703721L (sv) Forfarande for framstellning av hexahydroprimidinforeningar med terapeutisk verkan
SE385896B (sv) Forfarande for framstellning av 2,3-dihydro-4h-tieno-(3,2-c)(1)bensopyran-4-oner med analgetisk och antipyretisk verkan
SE415763B (sv) Forfarande for framstellning av 1,3-ditiolanyl(2)-och 1,3-ditianyl(2)-foreningar med koronardilaterande egenskaper
SE426319B (sv) Forfarande for framstellning av substituerade fenylketoner med sedativ, muskelrelaxerande och antikonvulsiv verkan
SE7507887L (sv) Forfarande for framstellning av bensopyranforeningar med terapeutisk verkan.
SE7510082L (sv) Polypeptid samt forfarande for framstellning av densamma
SE385696B (sv) Nytt forfarande for framstellning av n-(1-etyl-alfa-pyrrolidylmetyl)-2-metoxi-5-sulfamidobensamid med terapeutiska egenskaper
SE7608538L (sv) Forfarande for framstellning av substituerade fenylalkylaminoalkylbensenderivat med terapeutisk verkan
SE398230B (sv) Forfarande for framstellning av 1-amino-3-/(pyrrody-1)-fenoxi/-2-propanol och derivat derav med terapeutisk verkan
SE415659B (sv) Forfarande for framstellning av basiskt substituerade xanten- och tioxantenderivat
SE417206B (sv) Forfarande for framstellning av foreningar med autibiotisk verkan
SE7608115L (sv) Forfarande for framstellning av kinoxalinderivat med terapeutisk verkan
SE7713839L (sv) Forfarande for framstellning av indanderivat med terapeutisk verkan
SE7712219L (sv) Forfarande for framstellning av trans-5a-aryl-dekahydrobenzazpiner med terapeutisk verkan

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7509268-4

Effective date: 19890911

Format of ref document f/p: F